Solesence, Inc.

3.5100-0.18 (-4.88%)

Oct 29, 4:00:01 PM EDT · NasdaqCM · SLSN · USD

Upcoming Earnings

Report date

≈ Nov 5, 2025 (in 6 days)

Key Stats

Market Cap

247.39M

P/E (TTM)

43.88

Basic EPS (TTM)

0.08

Dividend Yield

Recent Filings

8-K

Solésence unveils leadership changes

9/4/25Sep 4, 2025

Solésence shakes up its C-suite on September 3, 2025, promoting Kevin Cureton from COO to CEO and President with a $367,000 base salary, appointing Laura Riffner as CFO at $270,000 after her stint at Nagase America, while Jess Jankowski steps down as CEO to become Board Advisor until retiring November 21. This trio aims to fuel innovation in skin health solutions amid the company's rebranding push. Leadership transitions demand seamless handoffs. Jankowski's exit caps 30 years of steering growth.

8-K

Shareholders approve key proposals

8/29/25Aug 29, 2025

Solésence shareholders convened their annual meeting on August 28, 2025, with 86.83% turnout electing R. Janet Whitmore and Laura M. Beres to the board amid minor withheld votes. They greenlit the 2025 Equity Compensation Plan by a wide margin, while ratifying RSM US LLP as auditors for the fiscal year. Governance stays steady. No surprises here.

10-Q

Q2 FY2025 results

8/14/25Aug 14, 2025

Solésence posted solid Q2 results, with revenue climbing 56% year-over-year to $20.4M, fueled by consumer products surging to $17.5M from $11.2M, while personal care ingredients added $2.7M. Gross profit hit $5.9M, yielding a 28.9% margin—up from 28.7% last year—despite higher volumes straining costs. Operating income rose to $1.9M, and net income jumped to $2.7M, boosted by $1.2M in other income from an Employee Retention Credit payment; diluted EPS matched $0.04 on 72.6M shares, consistent with the net figure. Cash ended at $4.1M after $7.9M operating outflow, offset by $11.8M in financing from related-party lines totaling $16.6M outstanding at 8.25%. Revenue relies heavily on three customers (73% share). Dependence on key clients poses risks if orders falter.

8-K

Q2 revenue up 56%

7/31/25Jul 31, 2025

Solésence reported Q2 2025 revenue surging 56% to $20.4 million, fueled by strong commercial execution and 102% higher shipment volumes versus last year. Gross profit climbed to $5.9 million at a steady 29% margin, while net income hit $2.7 million, boosted by a $1.2 million Employee Retention Credit receipt. The company expanded debt facilities to $23.0 million with maturity extended to April 2027, enhancing flexibility for growth. Revenue doubled year-over-year.

8-K

Name correction filed

6/9/25Jun 9, 2025

Solésence, Inc. filed a certificate of correction on June 3, 2025, fixing an omitted accent in its name change from Nanophase Technologies Corporation, originally amended on March 10, 2025. This minor tweak ensures the official name matches branding intent. No other alterations affect operations.

About

Solesence, Inc., a science-driven company, develops, manufactures, and sells integrated family of technologies in the United States. The company engages in engineered materials, formulation development, and commercial manufacturing. It also provides skin care formulations with mineral-based UV protection enabled by proprietary active pharmaceutical ingredients under the Solésence brand; skin health products, such as sunscreens and daily care products; and advanced material products, including architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, and medical diagnostics applications. The company was formerly known as Nanophase Technologies Corporation and changed its name to Solesence, Inc. in March 2025. Solesence, Inc. was incorporated in 1989 and is headquartered in Romeoville, Illinois.

CEO

Mr. Kevin Cureton

IPO

11/26/1997

Website

https://solesence.com

Employees

Sector

Consumer Defensive

Industry

Household & Personal Products